Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
EXPO files a Form 144 notice reporting proposed sales of restricted common stock.
The filing lists three restricted stock lots of 594, 568 and 510 shares with grant dates 03/11/2022, 03/11/2026 and 03/12/2021
Exponent Inc. Group Vice President Richard Reiss reported an open-market sale of 1,672 shares of Common Stock on May 19, 2026 at an average price of $58.6496 per share.
After this transaction, he directly holds 2,288 shares of Exponent common stock.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related share sales. On May 15, 2026, she exercised options for a total of 5,606 shares of common stock at strike prices of $29.05 and $25.405 per share, converting derivative awards into regular shares.
On the same date, she sold 4,194 shares of common stock in open-market transactions at an average price of $54.0595 per share. A footnote states these sales were made to cover the option exercise price and taxes, indicating a routine liquidity event rather than a purely discretionary sale. After these transactions, Corrigan directly owns 105,218 shares of Exponent common stock.
EXPO affiliate submitted a Form 144 notice to sell 4,194 shares of Common Stock via exercise of stock options on 05/15/2026. The filing also lists 10b5-1 sales by Catherine Corrigan in the prior three months: 3,909, 3,912, and 3,920 shares with gross proceeds reported.
Exponent Inc: Kayne Anderson Rudnick Investment Management, LLC reported beneficial ownership of 3,886,546 shares of Exponent Inc, representing 7.9% of the class as of 03/31/2026. The filing breaks down voting and dispositive power: sole voting power 2,839,655, shared voting power 1,042,670, sole dispositive power 2,843,876, and shared dispositive power 1,042,670.
Exponent Inc.’s Group Vice President Joseph Rakow reported an open-market sale of company stock. On May 13, 2026, he sold 2,945 shares of Exponent common stock at an average price of $54.6601 per share. Following this transaction, his directly held common stock position reported in this filing was 0 shares.
Exponent Inc. Group Vice President Joseph Sala reported an open-market sale of Common Stock. On May 13, 2026, he sold 2,066 shares at $56.66 per share. Following this transaction, the filing shows Sala directly holding 0 shares of Exponent common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of Common Stock of EXPO with a filing date of 05/13/2026. The filing lists two blocks of restricted stock dated 03/11/2026 and 03/11/2022.
Morgan Stanley Smith Barney LLC submitted a Form 144 relating to EXPO Common stock. The filing, dated 05/13/2026, lists proposed sales of Common shares identified as restricted stock including 986 shares issued 03/11/2026 and 1,080 shares issued 03/11/2022. The filing names NASDAQ as the market.
Exponent Inc Chief Financial Officer Eric R. Anderson filed an initial statement of beneficial ownership. He directly holds 2,955 shares of common stock. He also holds restricted stock units covering 4,750, 3,628, 3,538 and 3,000 shares of common stock on a 1-for-1 basis, plus options for 6,592 shares at an exercise price of $65.56 and 6,008 shares at $66.56 that become exercisable in four equal annual installments and expire in 2036.